EurekAlert!

New U.S. data demonstrate favorable safety profile and sustained, natural-looking improvements in lip augmentation with Teoxane’s RHA® 3 up to 12 months

Teoxane today announced the publication in the Aesthetic Surgery Journal of a pivotal randomized, controlled, double-blinded trial evaluating the safety and effectiveness of RHA® 3 for lip ...
Nasdaq

Revance Announces Transformative Aesthetics Portfolio Transaction with Exclusive U.S. Distribution Agreement of FDA-Approved Dermal Fillers from TEOXANE SA

- Revance gains access to the growing $1.1B U.S. filler market with three differentiated products, and plans to launch in second quarter 2020 - - Fast-tracks Revance’s commercial organization, and ...
Business Wire

Revance Commercial Infrastructure Established and Positioned to Launch Prestige Aesthetics Portfolio with the RHA® Collection of Dermal Fillers

NEWARK, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational ...
Business Wire

Revance Announces Transformative Aesthetics Portfolio Transaction with Exclusive U.S. Distribution Agreement of FDA-Approved Dermal Fillers from TEOXANE SA

NEWARK, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today ...